

10 March 2022
 ASX Code: MXC
 LSE Code: MXC

Joint Company Secretary Retirement

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that Mrs Rachel Kerr has retired from her role as Joint Company Secretary and has assumed a project management role within the Company's sales department having recently returned from maternity leave. Mrs Kerr has held the position of Company Secretary with the Company since the acquisition of MGC Pharmaceuticals in 2016, and will continue to assist the management team in her new position.

The Board would like to thank Rachel for her dedication to the role and the Company during her time as Company Secretary, including overseeing material transactions including the original ASX listing and more recently the dual listing on the London Stock Exchange. The Board and Company wish her the best in her new role.

Mr David Lim is now the sole Company Secretary for the Company.

--Ends--

Authorised for release by the Executive Chairman, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
 CEO & Managing Director
 +61 8 6382 3390
info@mgcpharma.com.au

UK Broker – Turner Pope

Andy Thacker
 +44 203 657 0050
info@turnerpope.com

MGC Pharmaceuticals Ltd

David Lim
 Company Secretary
 +61 8 6382 3390
info@mgcpharma.com.au

UK PR Advisors – Tavistock

Charles Vivian / Tim Pearson
 +44 207 920 3150
mgcpharma@tavistock.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    